Literature DB >> 2528389

A 6-hydroxydopamine-induced selective parkinsonian rat model.

D A Perese1, J Ulman, J Viola, S E Ewing, K S Bankiewicz.   

Abstract

Previous parkinsonian rat models have generally been characterized by unilateral destruction of both the nigrostriatal pathway and the mesolimbic pathway using the neurotoxin 6-hydroxydopamine (6-OHDA). We created a hemiparkinsonian model in which there is 6-OHDA-induced destruction of the dopaminergic nigrostriatal pathway but sparing of the dopaminergic mesolimbic pathway. This resulted in reproducible, quantifiable rotational behavior in response to either amphetamine or apomorphine and a near total depletion of dopamine in the striatum ipsilateral to the lesion with a dorsolateral distribution of supersensitive dopaminergic D2 receptors. This model parallels the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced hemiparkinsonian model in primates and more closely approximates the extent of neurodegeneration seen in human idiopathic Parkinson's disease than previous parkinsonian rat models. It may therefore prove a convenient model for studying the recently reported phenomenon of sprouting from host dopaminergic neurons following tissue implantation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528389     DOI: 10.1016/0006-8993(89)90597-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  39 in total

1.  Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.

Authors:  Mei Sun; Guo-Rong Zhang; Lingxin Kong; Courtney Holmes; Xiaodan Wang; Wei Zhang; David S Goldstein; Alfred I Geller
Journal:  Hum Gene Ther       Date:  2003-03-20       Impact factor: 5.695

Review 2.  Expression profile analysis of neurodegenerative disease: advances in specificity and resolution.

Authors:  Jason G Glanzer; Phillip G Haydon; James H Eberwine
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 3.  Gene expression profiling in neurological disorders: toward a systems-level understanding of the brain.

Authors:  Sergio E Baranzini
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

4.  Alterations in the proportions of skeletal muscle proteins following a unilateral lesion to the substantia nigra pars compacta of rats.

Authors:  A Sliwinski; D Stanic; D I Finkelstein; M Ilic; J M West; P C Dooley
Journal:  J Muscle Res Cell Motil       Date:  2005-07-01       Impact factor: 2.698

5.  Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.

Authors:  Chaoshi Niu; Jiaming Mei; Qi Pan; Xianming Fu
Journal:  Stereotact Funct Neurosurg       Date:  2009-02-18       Impact factor: 1.875

6.  The Effects of Crocin on 6-OHDA-Induced Oxidative/Nitrosative Damage and Motor Behaviour in Hemiparkinsonian Rats.

Authors:  Maryam Hosseini; Ziba Rajaei; Hojjatallah Alaei; Mohamadhasan Tajadini
Journal:  Malays J Med Sci       Date:  2016-12-07

7.  Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice.

Authors:  B Stauch Slusher; K C Rissolo; P F Jackson; L M Pullan
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.

Authors:  Hiroharu Maegawa; Hitoshi Niwa
Journal:  Methods Mol Biol       Date:  2021

9.  Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  Chieh-Sen Chuang; Hong-Lin Su; Fu-Chou Cheng; Shan-hui Hsu; Chi-Fen Chuang; Chin-San Liu
Journal:  J Biomed Sci       Date:  2010-02-13       Impact factor: 8.410

10.  The electrocorticogram signal can be modulated with deep brain stimulation of the subthalamic nucleus in the hemiparkinsonian rat.

Authors:  M J Lehmkuhle; S S Bhangoo; D R Kipke
Journal:  J Neurophysiol       Date:  2009-07-22       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.